Ewing Sarcoma | CHOP Research Institute
 

Ewing Sarcoma

This study involves taking a study drug called INBRX-109.

This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.

Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.
Published on
Oct 11, 2023
The Center for Precision Medicine for High-risk Pediatric Cancer Frontier Program builds upon ongoing precision medicine efforts across CHOP departments to define and expand treatment options.
Published on
Sep 22, 2023
Dr. Patrick Grohar will lead a research team to bring new therapies to clinical trial.

This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.

This study involves taking a study drug called lurbinectedin.

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Published on
Nov 30, 2022
The Emerging Innovators at CHOP Research Institute cover a variety of scientific disciplines.

The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma and when given in combination with topotecan and cyclophosphamide in patients with neuroblastoma.